Zydus’ Desidustat gets USFDA orphan drug status for sickle cell disease

Zydus Lifesciences announced a significant development today. The US Food and Drugs Administration has granted Orphan Drug Designation to Desidustat. This novel oral medication is intended for the treatment of Sickle Cell Disease. This designation supports the development of therapies for rare diseases. Zydus believes Desidustat can address an urgent medical need for patients.